Puromycin-sensitive aminopeptidase: An antiviral prodrug activating enzyme

Antiviral Research

Volumn 85, Issue 3, 2010, Pages 482-489

  Tehler, Ulrika ^a   Nelson, Cara H ^a   Peterson, Larryn W ^c   Provoda, Chester J ^a   Hilfinger, John M ^b   Lee, Kyung Dall ^a   McKenna, Charles E ^c   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TSRL INC   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aminopeptidase; Antiviral; Bioavailability; Cidofovir; Prodrug; Puromycin sensitive

Indexed keywords

ALANINE; AMINO ACID; AMINOPEPTIDASE; ANTIVIRUS AGENT; BESTATIN; CIDOFOVIR; PRODRUG; PUROMYCIN; SERINE; VALINE;

ARTICLE; CELL FREE SYSTEM; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG IDENTIFICATION; DRUG PURIFICATION; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

AMINOPEPTIDASES; ANTIVIRAL AGENTS; CACO-2 CELLS; CYTOSINE; HUMANS; KINETICS; PHOSPHONIC ACIDS; PRODRUGS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

HUMAN HERPESVIRUS 5; ORTHOPOXVIRUS; RODENTIA;

EID: 76949104697     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.12.003     Document Type: Article

References (43)

1. Acosta D., Goni F., and Carmona C. Characterization and partial purification of a leucine aminopeptidase from Fasciola hepatica. Journal of Parasitology 84 1 (1998) 1-7
2. Albert A. Chemical aspects of selective toxicity. Nature 182 4633 (1958) 421-422
3. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., and Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochemical and Biophysical Research Communications 250 2 (1998) 246-251
4. Bhutani N., Venkatraman P., and Goldberg A.L. Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO Journal 26 5 (2007) 1385-1396
5. Bischofberger N., Hitchcock M.J.M., Chen M.S., Barkhimer D.B., Cundy K.C., Kent K.M., Lacy S.A., Lee W.A., Li Z.-H., et al. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrobial Agents and Chemotherapy 38 10 (1994) 2387-2391
6. Botbol V., and Scornik O.A. Peptide intermediates in the degradation of cellular proteins. Bestatin permits their accumulation in mouse liver in vivo. The Journal of Biological Chemistry 258 3 (1983) 1942-1949
7. Constam D.B., Tobler A.R., Rensing-Ehl A., Kemler I., Hersh L.B., and Fontana A. Puromycin-sensitive aminopeptidase, sequence analysis, expression, and functional characterization. The Journal of Biological Chemistry 270 45 (1995) 26931-26939
8. Cundy K.C., Bidgood A.M., Lynch G., Shaw J.P., Griffin L., and Lee W.A. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metabolism and Disposition: The Biological Fate of Chemicals 24 7 (1996) 745-752
9. Cundy K.C., Li Z.H., Hitchcock M.J., and Lee W.A. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metabolism and Disposition: The Biological Fate of Chemicals 24 7 (1996) 738-744
10. Curran M., and Noble S. Valganciclovir. Drugs 61 8 (2001) 1145-1150 discussion 1151-1152
11. De Clercq E. In search of a selective antiviral chemotherapy. Clinical Microbiology Reviews 10 4 (1997) 674-693
12. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Research 55 1 (2002) 1-13
13. De Clercq E., and Holy A. Case history: acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Reviews. Drug Discovery 4 11 (2005) 928-940
14. Eriksson U., Peterson L.W., Kim J.-s., Mitchell S., Kijek P., Hilfinger J.M., Drach J.C., Kashemirov B.A., and McKenna C.E. Ehylene glycol-linked amino acid conjuagted of cyclic cidofovir: synthesis and biological activity. Antiviral Research 70 (2006) A58
15. Eriksson U., Hilfinger J.M., Kim J.S., Mitchell S., Kijek P., Borysko K.Z., Breitenbach J.M., Drach J.C., Kashemirov B.A., and McKenna C.E. Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Bioorganic & Medicinal Chemistry Letters 17 3 (2007) 583-586
16. Eriksson U., Peterson L.W., Kashemirov B.A., Hilfinger J.M., Drach J.C., Borysko K.Z., Breitenbach J.M., Kim J.S., Mitchell S., Kijek P., and McKenna C.E. Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Molecular Pharmaceutics 5 4 (2008) 598-609
17. Ganapathy M.E., Huang W., Wang H., Ganapathy V., and Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochemical and Biophysical Research Communications 246 2 (1998) 470-475
18. Goldberg A.L., and Rock K.L. Proteolysis, proteasomes and antigen presentation. Nature 357 6377 (1992) 375-379
19. Han H., de Vrueh R.L., Rhie J.K., Covitz K.M., Smith P.L., Lee C.P., Oh D.M., Sadee W., and Amidon G.L. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharmaceutical Research 15 8 (1998) 1154-1159
20. Hui K.S., Wang Y.J., and Lajtha A. Purification and characterization of an enkephalin aminopeptidase from rat brain membranes. Biochemistry 22 5 (1983) 1062-1067
21. Johnson G.D., and Hersh L.B. Studies on the subsite specificity of the rat brain puromycin-sensitive aminopeptidase. Archives of Biochemistry and Biophysics 276 2 (1990) 305-309
22. Kim I., Chu X.Y., Kim S., Provoda C.J., Lee K.D., and Amidon G.L. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. The Journal of Biological Chemistry 278 28 (2003) 25348-25356
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
24. Lazarus R.A., and Benkovic S.J. Mechanism of hydrolysis of phosphorylethanolamine triesters. Multiple catalytic effects of an intramolecular amino group. Journal of the American Chemical Society 101 15 (1979) 4300-4312
25. Lazarus R.A., Benkovic P.A., and Benkovic S.J. Mechanism of hydrolysis of phosphorylethanolamine diesters. Intramolecular nucleophilic amine participation. Journal of the Chemical Society 2 (1980) 373-379
26. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 193 1 (1951) 265-275
27. McKenna C.E., Kashemirov B.A., Eriksson U., Amidon G.L., Kish P.E., Mitchell S., Kim J.S., and Hilfinger J.M. Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry 690 10 (2005) 2673-2678
28. McKenna C.E., Kashemirov B.A., Peterson L.W., Eriksson U., Saejung K., Kim J.-S., Mitchell S., Kijek P., Hilfinger J.M., and Drach J.C. Cidofovir and Foscarnet peptide prodrugs. Antiviral Research 70 (2006) A37
29. McLellan S., Dyer S.H., Rodriguez G., and Hersh L.B. Studies on the tissue distribution of the puromycin-sensitive enkephalin-degrading aminopeptidases. Journal of Neurochemistry 51 5 (1988) 1552-1559
30. Mendel D.B., Cihlar T., Moon K., and Chen M.S. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrobial Agents and Chemotherapy 41 3 (1997) 641-646
31. Osada T., Ikegami S., Takiguchi-Hayashi K., Yamazaki Y., Katoh-Fukui Y., Higashinakagawa T., Sakaki Y., and Takeuchi T. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. Journal of Neuroscience 19 14 (1999) 6068-6078
32. Perry C.M., and Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52 5 (1996) 754-772
33. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., O'Grady J., Robinson C., To Z., Wren K., Banken L., Buhles W., and Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents and Chemotherapy 44 10 (2000) 2811-2815
34. Schnebli H.P., Phillipps M.A., and Barclay R.K. Isolation and characterization of an enkephalin-degrading aminopeptidase from rat brain. Biochimica et Biophysica Acta 569 1 (1979) 89-98
35. Schulz C., Perezgasga L., and Fuller M.T. Genetic analysis of dPsa, the Drosophila orthologue of puromycin-sensitive aminopeptidase, suggests redundancy of aminopeptidases. Development Genes and Evolution 211 12 (2001) 581-588
36. Sengupta S., Horowitz P.M., Karsten S.L., Jackson G.R., Geschwind D.H., Fu Y., Berry R.W., and Binder L.I. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 45 50 (2006) 15111-15119
37. Smiley M.L., Murray A., and de Miranda P. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Advances in Experimental Medicine and Biology 394 (1996) 33-39
38. Stoltze L., Schirle M., Schwarz G., Schroter C., Thompson M.W., Hersh L.B., Kalbacher H., Stevanovic S., Rammensee H.G., and Schild H. Two new proteases in the MHC class I processing pathway. Nature Immunology 1 5 (2000) 413-418
39. Tobler A.R., Constam D.B., Schmitt-Graff A., Malipiero U., Schlapbach R., and Fontana A. Cloning of the human puromycin-sensitive aminopeptidase and evidence for expression in neurons. Journal of Neurochemistry 68 3 (1997) 889-897
40. Towne C.F., York I.A., Neijssen J., Karow M.L., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Neefjes J.J., and Rock K.L. Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. Journal of Immunology 180 3 (2008) 1704-1712
41. Wachsman M., Petty B.G., Cundy K.C., Jaffe H.S., Fisher P.E., Pastelak A., and Lietman P.S. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Research 29 2,3 (1996) 153-161
42. Wagner G.W., Tavianini M.A., Herrmann K.M., and Dixon J.E. Purification and characterization of an enkephalin aminopeptidase from rat brain. Biochemistry 20 13 (1981) 3884-3890
43. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., and Smiley M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 54 6 (1993) 595-605